GLG News by Political Experts (outside Washington DC)

This bill can significantly impact commerce.  Product liability and the ability to import products from developing countries may be acutely affected. Analysis includes not only who the bill hurts, but who it may help.

The World Health Organization isn't going to let Altria's spinoff, Philip Morris International have a free ride in developing countries. With help from philanthropist New York Mayor Michael Bloomberg, the report highlights the scourge of global tobacco use, and efforts to get it under control.

Expect a window of opportunity in a wild west of genetic testing before abuse and a federal over-reaction.

A black box warning on Botox could harm Alergan (AGN).

Two new studies add to the safety data of off-label use of drug-eluting stents.

These lessons are valuable for considering new cancer research findings.     Just ask Genentech. Symbol: DNA

Pfizer(NYS:PFE)( :EQPFIZER), Eli Lilly and Forest Labs(NYS:FRX) are all hoping that it doesn't make a difference.

How will the FDA rule? What are the potential public health benefits? Are there risks of OTC statins?  Watching closely, will be Glaxo Smithkline (GSK), which will market OTC Mevacor. Approval could impact sales of Pfizer's Lipitor and other statins made by pharma's including AstraZeneca, Novartis...

This should keep defense lawyers busy not only for defendant, R.J. Reynolds Tobacco Co., but Altria, (Philip Morris) and Brown & Williamson - as it opens the door to similar cases against them, pending in Minnesota. The case will be watched, and may even have (limited) impact, on similar cases in...

The report, while critical of FDA, is more of a slap at Congress than the agency. It may remind Congress that consumers as well as the biotech and pharma industries rely on a healthy FDA. Moreover, it should serve to remind Congress to exercise caution before giving the agency increased regulator responsibility-...